COMMUNIQUÉS West-GlobeNewswire

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand

28/06/2018 - 13:30

WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with [...]

Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock

28/06/2018 - 13:30

SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of [...]

MPI: Orphan Drug designation on Oncology Venture's dovitinib for Adenoid Cystic Carcinoma

28/06/2018 - 13:16

Hoersholm, Denmark, June 28, 2018 -Medical Prognosis Institute A/S (MPI:ST) and Oncology Venture AB (OV:ST) announces that the Office of Orphan Products Development at the FDA has transferred the Dovitinib Orphan drug [...]

Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors

28/06/2018 - 13:04

Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors Phase I/II studies will evaluate Kymab’s lead investigational therapy [...]

Helius Medical Technologies, Inc. Announces MRI Confirmatory Evidence of Neuroplastic Change after Investigational PoNS™ Treatment Presented at the 2018 Joint Annual Meeting ISMRM – ESMRMB in Paris, France

28/06/2018 - 13:01

NEWTOWN, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that an [...]

Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100

28/06/2018 - 13:00

Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment and Evaluate Complete Clinical Trial Dataset Arsanis to Continue Focus on Development of ASN500 for Prevention of RSV Infection WALTHAM [...]

Capricor Therapeutics to Present at PPMD Annual Conference

28/06/2018 - 13:00

Poster Presentation on Pre-clinical Research of CAP-2003 in Disease Model of Duchenne Muscular Dystrophy LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics ’ (NASDAQ:CAPR) chief medical officer, [...]

Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering

28/06/2018 - 13:00

MALVERN, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who [...]

Innovate Biopharmaceuticals Enters into an R&D Collaboration on Larazotide’s Corrective Effect on the Dysfunctional Intestinal Barrier and the Dysfunctional Microbiome in various Diseases with the University of Maryland School of Medicine

28/06/2018 - 13:00

RALEIGH, N.C., June 28, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc . (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases, [...]

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

28/06/2018 - 13:00

The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a first-in-class potential [...]

Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs

28/06/2018 - 12:30

Board Comprises Six Members with Notable Contributions to the Fields of Oncology and Immunology BERKELEY, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the [...]

Hydropothecary reports fiscal 2018 third quarter results

28/06/2018 - 12:30

GATINEAU, Quebec, June 28, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (TSX:HEXO) (the "Company") reported its financial results for the three and nine months ended April 30, 2018, the third quarter of the [...]

Hydropothecary déclare les résultats du troisième trimestre de l’exercice 2018

28/06/2018 - 12:30

GATINEAU, Québec, 28 juin 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (TSX:HEXO) (la « Société ») a publié ses résultats financiers pour les périodes de trois et neuf mois closes le 30 avril 2018, à savoir le [...]

PotNetwork Holdings, Inc. Exhibits Swiftly Growing MediPets Line at Industry Leading SuperZoo Event

28/06/2018 - 12:00

MediPets Comes to Vegas Bringing the Latest in Pet CBD to the Largest Industry Event Geared Toward Professionals and Consumers Seeking Cutting-Edge Products and Education FT. LAUDERDALE, Fla., June 28, 2018 (GLOBE [...]

Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study

28/06/2018 - 11:00

Study Remains On-Track for Q3 2018 Top-Line Results BEDMINSTER, N.J., and DUBLIN, Ireland, June 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the [...]

Saniona awarded grant of SEK 1.4 million for Kv7 program

28/06/2018 - 10:40

PRESS RELEASE June 28, 2018 Saniona, a leading biotech company within ion-channel research, today announced that it that it has received a research grant of DKK 1 million (SEK 1.4 million) under the Danish Innovation [...]

Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3

28/06/2018 - 10:09

Bagsværd, Denmark, 28 June 2018 - Novo Nordisk today announced the headline results from PIONEER 3, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an [...]

Shire plc : Rule 2.9 announcement

28/06/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 28 June 2018 Shire [...]

Interim report September 1, 2017 - May 31, 2018

28/06/2018 - 08:00

Company announcement no.11/2018 Report attached For further information, please contact: Martin Riise, Head of Investor Relations Tel: +45 53 39 22 50 Helle Rexen, Interim Head of Media Relations Tel: +45 20 74 28 40 [...]